Search Results

You are looking at 81 - 90 of 381 items for :

  • "early detection" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

EPR24-099: Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico

Brenda Patricia Garza Badillo, David Hernández Barajas, José Luis González Vela, Ileana Cecilia Reynosa Silva, Luis Andrés González Torres, and Ana Patricia Sanchéz Fonseca

. Furthermore, this population requires a different approach by the internal medicine physician, especially based on palliative care. Therefore, national resources should be focused on cancer prevention and early detection programs. EPR24-099: TABLE 1

Full access

Evaluating the Potential Role of PET/CT in the Posttreatment Surveillance of Head and Neck Cancer

Shrujal S. Baxi, Lara Dunn, and David G. Pfister

The central rationale for active surveillance after curative treatment of head and neck squamous cell carcinoma (HNSCC) is the belief that earlier detection of recurrent or new primary cancers facilitates earlier initiation of therapy and can

Full access

Plenary Session—The Patient Journey: Equity of Cancer Care

Presented by: Thomas A. Farrington, Liz Margolies, Shonta Chambers, Maria D. Garcia-Jimenez, and Alyssa A. Schatz

Moderated by: Carmen E. Guerra

early or at a later stage, but it’s in the early detection/screening phase that cancer disparities become evident, according to Thomas A. Farrington, BSEE, Founder and President, Prostate Health Education Network (PHEN), and a member of the NCCN

Full access

Advancing the Standard of Cancer Care in 2014

Robert W. Carlson

-Risk Assessment: Colorectal in February 2014. Another interesting discussion centered on “Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?” During this point/counterpoint presentation, Peter R. Carroll, MD, MPH, and Andrew J

Full access

NCCN News

National Minority Quality Forum (NMQF) announced 3 key areas of policy focus as part of the Alliance for Cancer Care Equity (ACCE) joint collaboration, including advancing diversity in clinical trials, improving cancer screening and early detection, and

Full access

CLO22-063: Study on Correlation Between Serum CA 19-9 and Colorectal Carcinoma With Normal CEA

Avisikta Mallick and Arkaprovo Roy

the incidence of CRC among younger population has been attributed to the change in dietary habits and lifestyle. Therefore early detection is important. Tumors markers are long been studied for this purpose. CEA was first detected marker found to be

Full access

QIM24-191: Standardizing Height and Weight Measurement for Treatment Calculations in Adult Patients With Cancer

Lisa Tesoriero, Elizabeth Rodriguez, MaryAnn Connor, Jericho Garcia, Tiffany Lin, Mark Robson, Tiffany Traina, and Karen Collum

enforce the standard. A just culture, that promotes error reporting ensures early detection and correction. It's crucial to recognize the importance of accurate height and weight measurements and put systems in place to minimize errors.

Full access

CRE24-046: Social Determinants of Health in Real-World Evidence Studies of Early-Stage Cancer Care: A Systematic Literature Review

Thomas Wilson, Andrew Osterland, Sarah Markt, Arthur Sillah, Junqing Liu, Esther Renee Smith-Howell, Gregory Patton, and Kashif Firozvi

SDOH, this study identified data sources, definitions, and measures of SDOH used in observational studies of early-stage cancer. Methods: We conducted a systematic literature review of observational studies focused on the impact of SDOH on early

Full access

CLO21-024: Serial Circulating Tumor DNA Analysis for Treatment Monitoring in an Inflammatory Triple-Negative Breast Cancer Patient

Urmeel Patel, Nicole Hook, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey Aleshin, and Angel Rodriguez

inflammatory breast cancer and serial monitoring enables early detection of response/resistance to therapy prompting a timely change to an alternative therapy than the current standard of care.

Full access

BPI24-026: Utilization of ExoDx Prostate Test for Prostate Cancer Risk Stratification in the African American Population

Jason Alter, Ronald Tutrone, Christian J. Ray, Sonia Kumar, Grannum Sant, Yiyuan Yao, Vinita Verma, and Johan Skog

disease at every stage from prevention and screening to clinical outcomes, which calls for a focused approach to early detection and effective treatment options. The ExoDx Prostate (EPI) Test is a non-invasive risk assessment urine test for assessing risk